Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Radiation Oncology
•
Gastrointestinal Cancers
•
Pancreatic Cancer
How often do you see pseudoprogession in pancreatic cancer after SBRT, and how do you manage it if the patient is planed for surgical exploration?
Related Questions
Do you consider any "favorable" subset of patients with stage IV pancreatic cancer to be candidates for local pre-operative CRT and surgical resection?
Would you offer consolidative full dose chemo-RT for local residual pancreatic disease in a patient with stage IV pancreatic adenocarcinoma with excellent response after induction chemotherapy?
When using SBRT to treat unresectable pancreatic cancer after induction chemotherapy, do you treat elective lymph nodes?
For insurance, how do you justify medical necessity for IMRT to the pancreas in the preoperative, unresectable, and post-operative settings?
Would you offer post-operative radiation for a T2N0 rectal cancer with less than 12 lymph nodes found in the specimen after LAR?
Would you offer RT for a low-grade esophageal GIST if the patient was not a surgical candidate?
For a patient with a lung tumor that is radiographically consistent with early-stage NSCLC but pathology with characteristics overlapping with upper GI origin, what additional diagnostic procedures would you consider before treating?
How do you approach SBRT and constraining healthy liver for a small liver?
How would you approach consolidative rectal irradiation for a patient with liver-confined metastatic rectal adenocarcinoma, who has sustained a near-CR after CAPEOX, capecitabine, and ongoing bevacizumab?
Would you alter radiation recommendations for a patient with locally advanced rectal cancer and a history of abdominopelvic lymphoma radiation 40 years ago?
